ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages UroGen Pharma Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - URGN

Stock Information for UroGen Pharma Ltd.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About UroGen Pharma Ltd.

U.S. FDA Approves UroGen's ZUSDURI(TM) (mitomycin) for Intravesical Solution as the First and Only Medication for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)
The Gross Law Firm Notifies UroGen Pharma Ltd. Investors of a Class Action Lawsuit and Upcoming Deadline - URGN
DEADLINE ALERT for OGN, RCAT, URGN, FTRE: Law Offices of Howard G. Smith Reminds Investors of Opportunity to Lead Securities Fraud Class Actions
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of UroGen Pharma Ltd. - URGN
URGN CLASS ACTION: Invest in UroGen Pharma Ltd.? Contact BFA Law about the Pending Securities Fraud Class Action to Potentially Recover Losses (NASDAQ:URGN)
Shareholders that lost money on UroGen Pharma Ltd.(URGN) should contact The Gross Law Firm about pending Class Action - URGN
URGN LEGAL ALERT: BFA Law Notifies UroGen Pharma Ltd. Investors of the Imminent July 28 Securities Fraud Class Action Deadline
Faruqi & Faruqi Reminds UroGen Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of July 28, 2025 - URGN

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.